NCT05935748 - Ph2 Study NKT2152 with Palbociclib & Sasanlimab in Subjects with Advanced Clear Cell Renal Cell Carcinoma (ccRcc) | Biotech Hunter

Enrollment

172

Participants

Timeline

Start Date

July 28, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2026

Conditions

CcRCCClear Cell Renal Cell CarcinomaKidney CancerKidney NeoplasmsRenal CancerRenal NeoplasmsRecurrent Renal Cell CarcinomaMetastatic Renal Cell CarcinomaRefractory Renal Cell CarcinomaAdvanced Renal Cell CarcinomaCarcinomaNeoplasmsCarcinoma, Renal CellNeoplasms, Glandular and EpithelialNeoplasm by HistologyAdenocarcinomaUrologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteKidney DiseasesUrologic Diseases

Interventions

DRUG

NKT2152

Oral HIF2a inhibitor

DRUG

palbociclib

a cyclin-dependent kinases (CDK) 4 and 6 inhibitor

OTHER

sasanlimab

an immunoglobulin G4 (IgG4) monoclonal antibody that blocks PD-1; a solution for injection for subcutaneous administration

Trial Locations (8)

22908

University of Virginia Health System, Charlottesville

48109

University of Michigan-Rogel Cancer Center, Ann Arbor

60611

Northwestern University - Feinberg School of Medicine, Chicago

68130

Nebraska Cancer Specialists, Omaha

92093

University of California San Diego, La Jolla

02215

Dana-Farber Cancer Institute, Boston

10065-6094

Memorial Sloan Kettering Cancer Center, New York

75390-9324

UT Southwestern Medical Center, Dallas